Hypoglycemia
Hypoglycemia is a clinical syndrome characterized by abnormally low plasma glucose concentrations, typically below 70 mg/dL (3.9 mmol/L), resulting in a spectrum of neurogenic and neuroglycopenic symptoms. The pathogenesis of hypoglycemia involves an imbalance between glucose utilization and production, often due to excessive insulin or insulin secretagogue exposure, defects in counterregulatory hormone responses, critical illnesses, or inborn errors of metabolism. In individuals with diabetes, hypoglycemia is most commonly a consequence of exogenous insulin therapy or oral hypoglycemic agents, whereas in non-diabetic patients, causes may include insulinoma, adrenal insufficiency, or severe hepatic dysfunction. The health impacts of hypoglycemia are significant, ranging from transient autonomic symptoms such as palpitations, tremor, and diaphoresis to severe neurological impairment including confusion, seizures, loss of consciousness, and, in rare cases, irreversible brain injury or death. Recurrent episodes can impair quality of life, increase cardiovascular risk, and contribute to hypoglycemia unawareness, thereby raising the risk of severe events.
This type primarily affects individuals with diabetes mellitus, particularly those receiving insulin therapy or insulin secretagogues. It results from an excess of circulating insulin relative to physiological needs, often due to medication dosing errors, missed meals, increased physical activity, or altered insulin sensitivity. Insulin-induced hypoglycemia can be acute and severe, requiring immediate intervention to prevent neurological sequelae.
Reactive hypoglycemia occurs within several hours after eating, most commonly due to an exaggerated insulin response to carbohydrate ingestion. It is frequently observed in individuals with a history of gastric surgery or in those with early type 2 diabetes, and is characterized by symptoms such as weakness, hunger, and autonomic disturbances.
This form arises during periods of prolonged fasting or between meals, often as a consequence of underlying metabolic or endocrine disorders. Causes include hepatic insufficiency, adrenal insufficiency, hypopituitarism, or rare tumors such as insulinoma. Fasting hypoglycemia is typically more insidious in onset and may be associated with more severe neuroglycopenic manifestations.
Severe systemic illnesses such as sepsis, renal failure, or hepatic failure can disrupt glucose homeostasis through impaired gluconeogenesis, increased glucose consumption, or altered hormonal responses. This type of hypoglycemia is often seen in hospitalized patients and may be multifactorial in origin.
Apart from insulin, several medications can precipitate hypoglycemia, including sulfonylureas, meglitinides, quinine, pentamidine, and beta-blockers. This subtype is particularly relevant in elderly patients or those with polypharmacy, where drug interactions and impaired clearance may increase risk.
Hypoglycemia is a prevalent complication among individuals with diabetes mellitus, particularly those managed with insulin or sulfonylureas. Studies estimate that up to 90% of patients with type 1 diabetes experience at least one episode of symptomatic hypoglycemia annually, with severe episodes occurring in approximately 30–40%. In type 2 diabetes, the incidence of severe hypoglycemia is lower but rises with disease duration and insulin use, affecting an estimated 10–20% of patients per year. Non-diabetic hypoglycemia is less common, with insulinoma accounting for fewer than 10 cases per million person-years. Hospitalized patients, especially those with critical illnesses, are at increased risk, with hypoglycemia documented in 5–10% of intensive care admissions. Population-based studies indicate that hypoglycemia is associated with increased morbidity, healthcare utilization, and mortality, particularly among the elderly and those with comorbid cardiovascular disease.
The diagnosis of hypoglycemia is based on the presence of Whipple's triad: (1) symptoms consistent with hypoglycemia, (2) a low measured plasma glucose concentration, and (3) resolution of symptoms following glucose administration. Blood glucose should be measured using a reliable laboratory method at the time of symptoms. In ambiguous cases, a supervised fasting test may be employed to provoke hypoglycemia and document concomitant insulin, C-peptide, proinsulin, and counterregulatory hormone levels, aiding in the identification of endogenous hyperinsulinemic states such as insulinoma. Additional diagnostic work-up may include assessment of renal and hepatic function, cortisol and ACTH levels, and imaging studies (e.g., abdominal ultrasound, CT, or MRI) to localize insulin-secreting tumors. Continuous glucose monitoring can be useful in detecting asymptomatic or nocturnal episodes, particularly in patients with hypoglycemia unawareness. Differential diagnosis should consider factitious hypoglycemia, critical illness, and inborn errors of metabolism, with the diagnostic approach tailored to the clinical context and patient risk factors.
Dasiglucagon is a glucagon analog administered for the rapid treatment of severe hypoglycemia, providing a ready-to-use, stable formulation that facilitates prompt restoration of blood glucose levels. Glucagon, available in both injectable and intranasal forms, is indicated for the emergency management of severe hypoglycemia when oral carbohydrate administration is not feasible; intranasal glucagon offers a needle-free alternative for rapid intervention. Recombinant human glucagon, produced via rDNA technology, serves as another parenteral option for reversing hypoglycemic episodes, particularly in patients unable to ingest carbohydrates. Diazoxide is an oral antihypertensive agent with hyperglycemic properties, used to manage hypoglycemia secondary to hyperinsulinism by inhibiting insulin release from pancreatic beta cells, thus elevating plasma glucose concentrations in both congenital and acquired forms of hyperinsulinemic hypoglycemia.
| Structure | Generic Name | CAS Registry Number | Molecular Formula | Molecular Weight |
|---|---|---|---|---|
 | dasiglucagon (Rec INN; USAN) | 1544300-84-6 | C152 H222 N38 O50 | 3381.614 |
| glucagon (intranasal) | ||||
| glucagon | ||||
| glucagon (rDNA origin); recombinant human glucagon | ||||
 | diazoxide (Rec INN; USAN; BAN) | 364-98-7 | C8 H7 Cl N2 O2 S | 230.671 |
Make Order
Experimental Scheme
Implementation
Conclusion
